Phase 1 Multiple Sclerosis Trial, Not Yet Recruiting NCT07606521 Sponsor: Polpharma Biologics International AG Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 1 Multiple Sclerosis Trial, Not Yet Recruiting

NCT07606521
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), confirmed using a specific set of diagnostic standards called the revised McDonald criteria.
  • People who have shown signs of recent disease activity, as defined by the trial's guidelines.
  • People whose neurological condition has been stable for at least 30 days before both the initial screening appointment and the first treatment in the study.
  • People with RMS whose disability level (measured by a standard scale called the EDSS) falls between 0 and 6.0, or people with PPMS whose EDSS score falls between 3.0 and 6.5.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have had an RMS diagnosis for more than 10 years and whose EDSS score at screening is 2.0 or lower.
  • People who have had a PPMS diagnosis for less than 10 years with an EDSS score of 5.0 or lower at screening, or for less than 15 years with an EDSS score above 5.0 at screening.
  • People who are unable to have an MRI scan, or for whom an MRI scan is medically inadvisable.
  • People who have a known allergy, serious sensitivity, or medical reason to avoid corticosteroids (including methylprednisolone) or other ingredients used in the study treatments.
  • People who have, or have had in the past, certain medical conditions listed in the trial protocol (confirm with trial site).
  • People who have recently received, or are planned to receive, certain medications or treatments that are not permitted under the trial protocol (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Polpharma Biologics International AG
Registry
ClinicalTrials.gov
Start date
1 October 2026
Est. completion
1 December 2027

Primary endpoints

Area under the concentration time curve

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov